

Faculty Disclosures

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, course directors, planners, moderators, faculty, and all others in control of the educational content of the continuing education activity must disclose all financial relationships with ineligible companies that they may have had within the past 24 months. If an individual refuses to disclose financial relationships, they will be disqualified from being a part of the planning and implementation of the activity. Owners and/or employees of an ineligible company with business lines or products relating to the content of the activity will not be permitted to participate in the planning or execution of any accredited program. All listed relevant financial relationships with ineligible companies for individuals in control of content have been mitigated.

Name	Role in Activity	Ineligible Company	Nature of Relevant Financial Relationship
Bedard	Speaker	• None	• N/A
Datte	Speaker	• None	• N/A
Davis	Speaker	• None	• N/A
DeLucia	Moderator, Planning Committee	• None	• N/A
Freeman	Moderator, Planning Committee	• None	• N/A
Hawk	Speaker	• None	• N/A
Johnston	Moderator, Planning Committee	• None	• N/A
Kosty	Speaker	• None	• N/A
Lettkeman	Moderator, Planning Committee	• None	• N/A
McNeill	Speaker	• None	• N/A
McQuade	Speaker	• Bristol Myers Squibb, Roche • Merck	• Speaker • Consultant
Mishaw	Moderator, Planning Committee	• None	• N/A
Mistry	Speaker	• AstraZeneca • Genentech	• Advisory Board, Speaker • Advisory Board
Mohan	Speaker	• Abbott, Akcea Therapeutics, Alnylam Pharmaceuticals, Pfizer • CareDX, Eidos Therapeutics	• Speaker • Consultant
Narayanan	Speaker	• None	• N/A
Navai	Speaker	• Aduro BioTech, Inc. • Allogene Therapeutics	• Scientific Advisory Committee Member • Stock
Nortjé	Speaker	• None	• N/A
Reeder	Speaker	• None	• N/A
Richards	Speaker	• Bristol Myers Squibb, GSK, Takeda	• Consultant

Skwira-Brown	Speaker	<ul style="list-style-type: none"> • None 	<ul style="list-style-type: none"> • N/A
Suhar	Speaker	<ul style="list-style-type: none"> • None 	<ul style="list-style-type: none"> • N/A
Vo	Moderator, Planning Committee	<ul style="list-style-type: none"> • None 	<ul style="list-style-type: none"> • N/A
Westin	Speaker	<ul style="list-style-type: none"> • ADC Therapeutics, AstraZeneca, Bristol Myers Squibb, Genentech, Gilead, Ikusuda, Morphosys, Novartis, Umoja • ADC Therapeutics, AstraZeneca, Bristol Myers Squibb, Genentech, Gilead, Morphosys, Novartis 	<ul style="list-style-type: none"> • Consultant • Research Funding
Xavier	Speaker	<ul style="list-style-type: none"> • AbbVie, Acrotech Biopharma, AstraZeneca, BeiGene, Bristol-Myers Squibb/Celgene, Epizyme, Genentech, Incyte Corporation, MorphoSys, Seattle Genetics 	<ul style="list-style-type: none"> • Advisor, Speaker
CME Committee	CE approval, all final decision-making on activities	<ul style="list-style-type: none"> • None 	<ul style="list-style-type: none"> • N/A
Scripps Conference Services & CME	Plan, manage, implement, and reconcile CE activities	<ul style="list-style-type: none"> • None 	<ul style="list-style-type: none"> • N/A

Glossary of Terms

Ineligible Company

An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. For specific examples of ineligible companies visit [scrippsmdanderson.com](#).

Financial Relationships

Financial relationships include employee, researcher, consultant, advisor, speaker, independent contractor, research funding, royalties or patent beneficiary, executive role, and ownership interest. Individual stocks and stock options should be disclosed.